Literature DB >> 6460586

Clodronate kinetics and bioavailability.

G J Yakatan, W J Poynor, R L Talbert, B F Floyd, C L Slough, R S Ampulski, J J Benedict.   

Abstract

Carbon 13-labeled clodronate disodium was given to healthy adult men by intravenous infusion and orally in a crossover design. Serum and urine levels were determined as a function of time by isotope-ratio mass spectrometry. Clodronate disodium (Cl2/MDP) is primarily excreted unchanged by the kidney; more than 80% of the intravenous dose was recovered within 48 hr. The serum concentrations-time curve over the first 8 hr after intravenous dosing appears biexponential with the disposition phase having a harmonic mean half-life (t 1/2) of 2 hr. The mean serum clearance was found to be 1.4 ml min-1 kg-1 and the apparent volume of distribution was approximately 25% of body weight. Simulations and computer fitting of the cumulative urinary excretion and urinary excretion rates based on the biexponential serum decay curve demonstrated the presence of a slow disposition component with a t 1/2 of 12.8 hr. Thus, the disposition kinetics of Cl2MDP appear to be triexponentials, although the slowest component is not of major significance after a single dose and could not be verified because of a lack of serum data after 8 hr. Cl2MDP is poorly absorbed with an absolute bioavailability of only 1% to 2%.

Entities:  

Mesh:

Substances:

Year:  1982        PMID: 6460586     DOI: 10.1038/clpt.1982.51

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  28 in total

1.  The effect of dosing regimen on the pharmacokinetics of risedronate.

Authors:  D Y Mitchell; M A Heise; K A Pallone; M E Clay; J D Nesbitt; D A Russell; C W Melson
Journal:  Br J Clin Pharmacol       Date:  1999-10       Impact factor: 4.335

2.  Bioavailability prediction based on molecular structure for a diverse series of drugs.

Authors:  Joseph V Turner; Desmond J Maddalena; Snezana Agatonovic-Kustrin
Journal:  Pharm Res       Date:  2004-01       Impact factor: 4.200

3.  The clearance and bioavailability of pamidronate in patients with breast cancer and bone metastases.

Authors:  P T Daley-Yates; D J Dodwell; M Pongchaidecha; R E Coleman; A Howell
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 4.  Bisphosphonates. Pharmacology and use in the treatment of tumour-induced hypercalcaemic and metastatic bone disease.

Authors:  H Fleisch
Journal:  Drugs       Date:  1991-12       Impact factor: 9.546

5.  Isotope retention for assessment of bone turnover in involutional osteoporosis.

Authors:  M Passeri; E Palummeri; M C Baroni; F Quaini; A Quintavalla; M Barbagallo; D Franchini; D Ugolotti
Journal:  Clin Rheumatol       Date:  1989-06       Impact factor: 2.980

6.  Risedronate pharmacokinetics and intra- and inter-subject variability upon single-dose intravenous and oral administration.

Authors:  D Y Mitchell; W H Barr; R A Eusebio; K A Stevens; F P Duke; D A Russell; J D Nesbitt; J H Powell; G A Thompson
Journal:  Pharm Res       Date:  2001-02       Impact factor: 4.200

7.  Inhibition of bone resorption by bisphosphonates: interactions between bisphosphonates, osteoclasts, and bone.

Authors:  A M Flanagan; T J Chambers
Journal:  Calcif Tissue Int       Date:  1991-12       Impact factor: 4.333

Review 8.  Bisphosphonates and the treatment of bone disease in the elderly.

Authors:  A Johansen; M Stone; F Rawlinson
Journal:  Drugs Aging       Date:  1996-02       Impact factor: 3.923

Review 9.  Drugs used in the treatment of metabolic bone disease. Clinical pharmacology and therapeutic use.

Authors:  S Patel; A R Lyons; D J Hosking
Journal:  Drugs       Date:  1993-10       Impact factor: 9.546

10.  Long-term release of clodronate from biodegradable microspheres.

Authors:  P Perugini; I Genta; B Conti; T Modena; F Pavanetto
Journal:  AAPS PharmSciTech       Date:  2001-07-11       Impact factor: 3.246

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.